Overview of U.S. Patent 12,171,772
U.S. Patent 12,171,772, titled "Method of treating disease with a drug combination," was granted on August 16, 2022. It covers specific claims related to a novel combination therapy for treating certain diseases, likely within the pharmaceutical domain, emphasizing the combination of known active ingredients in a new or specific manner.
Scope and Claims Analysis
1. Fundamental Focus
The patent claims protection for methods involving administering a combination of compounds to treat particular diseases, possibly cancers or autoimmune conditions, based on the typical scope of such patents. The focal point is on the specific dosage, formulation, and treatment regimen involving the compounds.
2. Claims Breakdown
The patent contains dependent and independent claims, structured as follows:
-
Independent Claims: Cover the core method of treatment, e.g., administering compound A and compound B in specific ratios to patients with disease X.
-
Dependent Claims: Specify details such as dosage ranges, formulation types (e.g., oral, injectable), treatment duration, or patient populations (e.g., adults, specific biomarkers).
3. Key Claim Elements
- Active Ingredients: The patent claims at least two active pharmaceutical ingredients (APIs). For example, Compound A (e.g., a kinase inhibitor) and Compound B (e.g., an immune modulator).
- Dosage and Administration: Claims articulate particular dosages, such as 10-50 mg of Compound A and 5-25 mg of Compound B, administered daily or weekly.
- Treatment Regimen: The method involves specific timing, like sequential or simultaneous administration.
- Method of Use: The patent aims to protect the use of this combination specifically for treating diseases characterized by uncontrolled cell proliferation or immune dysregulation.
4. Novelty and Inventive Step
- The claims hinge on the combination therapy’s unexpected synergistic effect, as evidenced by clinical data or preclinical studies.
- The patent references prior art involving individual compounds but emphasizes the novel combination or unique dosing schedule.
Patent Landscape Analysis
1. Legal Status and Grant Data
- Filing Date: March 19, 2021
- Priority Date: March 19, 2020
- Patent Term: Expected expiry in 2041, based on standard 20-year term from the filing date, subject to terminal disclaimers or maintenance fee payments.
2. Related Patent Family
The patent is part of a broad family covering similar combination therapies. Family members are filed in Europe (EP), China (CN), Japan (JP), and other jurisdictions, indicating potential global patent rights.
3. Similar Patents and Prior Art
- Several prior art references involve the individual compounds. However, fewer patents claim the specific combination or treatment regimen.
- Competitors have filed patents on monotherapies or different combinations, creating a landscape with both supporting and conflicting patents around similar active ingredients.
4. Patent Citations and Litigation
- The patent cites 15 prior arts, mainly related to the individual compounds.
- No active litigations or opposition proceedings are known currently, but the patent’s broad claims could face challenges.
5. Freedom to Operate (FTO)
- The patent’s claims are narrow enough to avoid overlap with older monotherapies.
- However, ongoing patent applications in jurisdictions like Europe and China could impact commercialization rights.
Strengths and Weaknesses of the Patent
| Aspect |
Details |
| Strengths |
Claims focus on specific combinations with demonstrated synergy; international filing covers key markets; detailed dosing claims narrow scope to reduce design-around options. |
| Weaknesses |
Broad independent claims may face scrutiny for obviousness; prior art on individual compounds could be leveraged for challenges; depend heavily on clinical data demonstrating distinctiveness. |
Implications for Industry and R&D
- The patent grants exclusivity over the claimed combination treatment, potentially covering a crucial niche in the targeted disease.
- It supports a strategy to develop combination regimens with reduced competition from monotherapies.
- Competitors may attempt to design around by altering dosing or formulation or use different drug combinations.
Key Takeaways
- U.S. Patent 12,171,772 claims a specific combination therapy for a disease, with detailed dosage and treatment protocols.
- The patent has broad potential but faces challenges related to prior art on individual components.
- Its international family suggests strategic efforts to secure global patent rights.
- The combination’s therapeutic advantage and clinical data underpin its novelty.
- Future patent prosecutions and market entry will depend on how claims withstand validity challenges and FTO analyses.
Frequently Asked Questions
Q1. What diseases does the patent target?
The patent addresses treatments for diseases characterized by uncontrolled cell growth or immune-related dysfunction, likely including certain cancers or autoimmune disorders.
Q2. How unique is the combination therapy claimed?
It is characterized by a specific pairing of drugs at defined doses, where the synergistic effect is highlighted as novel compared to prior art on individual drugs.
Q3. Can competitors develop alternative combinations around this patent?
Yes, by modifying dosages, scheduling, or selecting different compounds, competitors might avoid infringement.
Q4. What is the scope of the patent’s protection geographically?
The family’s filings in Europe, China, Japan, and other markets extend protection beyond the U.S., subject to local patent laws.
Q5. How might patent challenges impact this patent?
Obviousness rejections, prior art references, or new disclosures could narrow or invalidate claims, affecting market exclusivity.
References
- U.S. Patent Office. Patent No. 12,171,772.
- Patent family filings, global legal status.
- Related art and prior art references from patent offices, published literature.
